<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703868</url>
  </required_header>
  <id_info>
    <org_study_id>YJ26-101</org_study_id>
    <nct_id>NCT04703868</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects</brief_title>
  <official_title>A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yungjin Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yungjin Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to&#xD;
      Rabeprazole in healthy adult subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to&#xD;
      Rabeprazole in healthy adult subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Integrated gastric acidity</measure>
    <time_frame>From Day 1 up to Day 28</time_frame>
    <description>Percent decrease from baseline in integrated gastric acidity for 24 hour interval after 7th dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent decrease from baseline in integrated gastric acidity for 24 hour interval after 1 st dose</measure>
    <time_frame>24 hours</time_frame>
    <description>Evaluateion PD Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of time with gastric pH&gt;4 for 24 hour interval after 1st and 7th dose</measure>
    <time_frame>From Day 1 up to Day 28</time_frame>
    <description>Evaluateion PD Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and median gastric pH after 1st and 7th dose</measure>
    <time_frame>From Day 1 up to Day 28</time_frame>
    <description>Evaluateion PD Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCÏ„</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss,</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav,ss,</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss/F</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Evaluateion PK Rabeprazole after multiple dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>YPI-011 10/500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: 1 tablet administered before the breakfast during 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YPI-011 20/500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: 1 tablet administered before the breakfast during 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole Sodium 10mg</intervention_name>
    <description>Part A: 1 tablet administered before the breakfast during 7 days</description>
    <arm_group_label>YPI-011 10/500mg</arm_group_label>
    <other_name>Reference drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole Sodium 20mg</intervention_name>
    <description>Part B: 1 tablet administered before the breakfast during 7 days</description>
    <arm_group_label>YPI-011 20/500mg</arm_group_label>
    <other_name>Reference drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19~55 years in healthy volunteers&#xD;
&#xD;
          -  BMI is more than 18.0 kg/m^2 , no more than 28.0 kg/m^2&#xD;
&#xD;
          -  Subjects who have ability to comprehend the objectives, contents of study and property&#xD;
             of study drug before participating in trial and have willingness to sign of informed&#xD;
             consent in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of medical history or a concurrent disease that may interfere with treatment&#xD;
             and safety assessment or completion of this clinical study, including clinically&#xD;
             significant disorders in digestive system, neuropsychiatric system, endocrine system,&#xD;
             liver, cardiovascular system&#xD;
&#xD;
          -  Subjects who were judged ineligible by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seunghwan Lee, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yungjin Pharm</last_name>
    <phone>82-2-2041-8325</phone>
    <email>dhkwon1201@yungjin.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Daehak-ro Jongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

